Login / Signup

Medium optimization and subsequent fermentative regulation enabled the scaled-up production of anti-tuberculosis drug leads ilamycin-E1/E2.

Zhiying FanNian TongZhoukang ZhuangCheng MaJunying MaJianhua JuYanwen DuanXiangcheng Zhu
Published in: Biotechnology journal (2022)
Our work has provided a solid basis to acquire sufficient ilamycin-E1/E2 lead compounds and then support their potential anti-TB drug development.
Keyphrases
  • mycobacterium tuberculosis
  • adverse drug
  • pulmonary tuberculosis
  • hiv aids
  • emergency department